Day: February 1, 2021

Ashland commits to Science Based Targets initiative and becomes signatory to the United Nations Global Compact furthering the company’s ESG agenda

Written by Customer Service on February 1, 2021. Posted in Public Companies.

Wilmington, Del., Feb. 01, 2021 (GLOBE NEWSWIRE) — Ashland is joining the global movement of leading companies and aligning operations with the ambitious aim of the Paris Climate Accord to limit global temperature rise to 1.5°C above preindustrial levels. Ashland has also committed to making the UN Global Compact and its principles part of the company’s business strategy, culture and day-to-day operations, and will engage in collaborative projects which advance the broader development goals of the United Nations, particularly the Sustainable Development Goals.“Science-based targets provide a clearly-defined path to reduce greenhouse gas emissions,” said Guillermo Novo, chairman and chief operating officer, Ashland. “We support public accountability and transparency, and we commit to reporting our progress. These initiatives reinforce...

Trevi Therapeutics Appoints William Forbes, Pharm.D. as Chief Development Officer

Written by Customer Service on February 1, 2021. Posted in Public Companies.

Industry Veteran to Lead the Clinical Development of Haduvio™ in Multiple IndicationsNEW HAVEN, Conn., Feb. 01, 2021 (GLOBE NEWSWIRE) — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the appointment of William Forbes, Pharm.D., as Chief Development Officer. Dr. Forbes will join Trevi’s senior management team and be responsible for leading the clinical development of Haduvio which is in late-stage clinical trials in its two lead indications.“I am happy to welcome Bill to our executive leadership team,” said Jennifer L. Good, President and Chief Executive Officer of Trevi. “Bill has a proven track record of success in developing and managing highly effective...

Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis

Written by Customer Service on February 1, 2021. Posted in Public Companies.

Roflumilast cream demonstrated statistically significant superiority over vehicle on primary endpoint of IGA SuccessFavorable safety and tolerability profile in this patient populationNew Drug Application (NDA) submission anticipated in the second half of 2021Roflumilast cream potential “Best in Class” topical PDE4 inhibitor, a non-steroidal treatment intended for chronic usePlaque psoriasis affects approximately 8.6 million patients in the U.S.Company to host a conference call today at 8:30 a.m. ESTWESTLAKE VILLAGE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today announced positive topline results from the DERMIS-1 and DERMIS-2 pivotal Phase 3 studies...

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”

Written by Customer Service on February 1, 2021. Posted in Public Companies.

VANCOUVER, British Columbia, Feb. 01, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin). Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.Algernon has also filed new provisional patents for new forms of DMT, in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed...

Critical Care Antiarrhythmic Drugs Market Size Worth USD 1,319.7 Million at 5.6% CAGR; Industry Leaders Such as Pfizer and Novartis to Invest Heavily in Research & Development: Fortune Business Insights™

Written by Customer Service on February 1, 2021. Posted in Mergers And Acquisitions.

Pune, India, Feb. 01, 2021 (GLOBE NEWSWIRE) — The global critical care antiarrhythmic drugs market size is projected to reach USD 1,319.7 million by 2027, exhibiting a CAGR of 5.6% during the forecast period. Increasing prevalence of cardiovascular diseases (CVDs) around the world will be a major growth determinant for this market, highlights Fortune Business Insights™ in its report, titled “Critical Care Antiarrhythmic Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Beta Blockers, Calcium Channel Blockers, Sodium Channel Blockers, Potassium Channel Blockers, and Others), By Disease Type (Supraventricular Arrhythmias, Ventricular Arrhythmias, and Others), and Regional Forecast, 2020-2027”.According to the World Health Organization (WHO), CVDs are the premier cause of global deaths, killing nearly 17.9 million...

Form 8.3 – Applegreen Plc

Written by Customer Service on February 1, 2021. Posted in Mergers And Acquisitions.

Ap19FORM 8.3IRISH TAKEOVER PANELDISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANELACT, 1997, TAKEOVER RULES, 2013DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE1. KEY INFORMATION2. INTERESTS AND SHORT POSITIONS(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) Ap201. DEALINGS (Note 4)(a) Purchases and sales (b) Derivatives transactions (other than options transactions)(c) Options transactions in respect of existing relevant securities(i) Writing, selling, purchasing or varying(ii) Exercising(d) Other dealings (including transactions in respect of new securities) (Note 4)Ap212. OTHER INFORMATIONAgreements,...

VSBLTY AND SYNQ PARTNER TO PROVIDE PUBLIC HEALTH SAFETY, SECURITY TECHNOLOGY FOR VICTORIA, BC CANADIAN TIRE STORE

Written by Customer Service on February 1, 2021. Posted in Public Companies.

Philadelphia, PA, Feb. 01, 2021 (GLOBE NEWSWIRE) — VSBLTY Groupe Technologies Corp. (CSE: VSBY) (Frankfurt 5VS) (OTC: VSBGF) (“VSBLTY”), a leading provider of security and retail marketing technology, is partnering with SYNQ, a Canadian innovative retail security and customer experiential technology company, to co-develop a public safety, security solution for Canadian Tire’s third largest location located in Hillside Mall, Victoria, B.C.SYNQ will utilize VSBLTY’s state-of-the-art software Vector™ in the Canadian Tire store deployment. This proprietary technology, driven by artificial intelligence and machine learning, provides real time occupancy data that will enable this store to automate functions that are normally performed manually. Commenting on the new contract, VSBLTY Co-founder & CEO Jay Hutton said, “We are especially...

Progressive Care Completes Expansion, Launches COVID-19 Rapid Testing at New Orlando Location

Written by Customer Service on February 1, 2021. Posted in Public Companies.

MIAMI, FL, Feb. 01, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Progressive Care Inc. (OTCQB:RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is excited to announce that its new 3,700 square foot Orlando pharmacy has now officially opened for business as a potent full-service location that is also expected to act as a growth hub for rapid results viral testing services, Covid-19 vaccinations, and 340B third-party administration contracting.The move will allow for a dramatic expansion in services of PharmCoRx pharmacy medication therapy and medication adherence management, and Covid-19 rapid testing solution.The new location sits just minutes from Orlando International Airport, which will facilitate ease of access for international and out-of-state travelers in need of rapid results...

uniQure to Participate in Multiple Upcoming Industry Conferences in February

Written by Customer Service on February 1, 2021. Posted in Public Companies.

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 01, 2021 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:14th Annual Congress of the European Association of Hemophilia and Allied Disorders (EAHAD), February 3 – 5, 2021• uniQure will deliver multiple presentations on the company’s gene therapy candidate etranacogene dezaparvovec in patients with hemophilia B. These presentations will include encore clinical data first presented at medical conferences late last year, as well as health economic data.• Further details on the company’s presentations will follow closer to the conference dates.Gene Therapy Medical Affairs,...

Fresenius Medical Care North America Enhances Nationwide Distribution of Home Dialysis Machines and Supplies with Descartes Last Mile Delivery Solution

Written by Customer Service on February 1, 2021. Posted in Public Companies.

Solution Supports Growth of Home Dialysis, Improves Customer Experience, and Creates Efficiencies with Fleet ManagementWALTHAM, Mass. & WATERLOO, Ontario, Feb. 01, 2021 (GLOBE NEWSWIRE) — Fresenius Medical Care North America (FMCNA), the nation’s leading provider of kidney care products and services, and Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announce the rollout of Descartes’ last mile delivery solution to improve the distribution of equipment and services to home patients and dialysis centers across the U.S.“We take great pride in the superior care we give to our patients and the best-in-class service we provide to our customers,” said Scott McLean, Director of Transportation at FMCNA. “Our distribution operations are fundamental to this commitment...

Day: February 1, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals